364 related articles for article (PubMed ID: 11684056)
41. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
42. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.
Chan P; Di Monte DA; Langston JW; Janson AM
J Pharmacol Exp Ther; 1997 Jan; 280(1):439-46. PubMed ID: 8996226
[TBL] [Abstract][Full Text] [Related]
43. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
44. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.
Tabatabaei A; Perry TL; Hansen S; Krieger C
Neurosci Lett; 1992 Jul; 141(2):192-4. PubMed ID: 1436633
[TBL] [Abstract][Full Text] [Related]
45. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Watanabe Y; Kato H; Araki T
Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
[TBL] [Abstract][Full Text] [Related]
46. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
[TBL] [Abstract][Full Text] [Related]
47. Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Kadoguchi N; Kimoto H; Yano R; Kato H; Araki T
Metab Brain Dis; 2008 Jun; 23(2):147-54. PubMed ID: 18425568
[TBL] [Abstract][Full Text] [Related]
48. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
49. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice.
Dluzen DE
Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629
[TBL] [Abstract][Full Text] [Related]
50. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
51. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse.
Janson AM; Fuxe K; Goldstein M
Clin Investig; 1992; 70(3-4):232-8. PubMed ID: 1521037
[TBL] [Abstract][Full Text] [Related]
52. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Kuroiwa H; Yokoyama H; Kimoto H; Kato H; Araki T
Metab Brain Dis; 2010 Jun; 25(2):177-83. PubMed ID: 20431930
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies.
Mori S; Fujitake J; Kuno S; Sano Y
Neurosci Lett; 1988 Jul; 90(1-2):57-62. PubMed ID: 2901058
[TBL] [Abstract][Full Text] [Related]
54. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.
Kupsch A; Löschmann PA; Sauer H; Arnold G; Renner P; Pufal D; Burg M; Wachtel H; ten Bruggencate G; Oertel WH
Brain Res; 1992 Oct; 592(1-2):74-83. PubMed ID: 1360317
[TBL] [Abstract][Full Text] [Related]
55. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
56. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
57. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
58. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Battaglia G; Busceti CL; Molinaro G; Biagioni F; Storto M; Fornai F; Nicoletti F; Bruno V
J Neurosci; 2004 Jan; 24(4):828-35. PubMed ID: 14749427
[TBL] [Abstract][Full Text] [Related]
59. Minocycline enhances MPTP toxicity to dopaminergic neurons.
Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
[TBL] [Abstract][Full Text] [Related]
60. Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
Brain Res Bull; 2001 Sep; 56(1):55-60. PubMed ID: 11604249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
